Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuhang Wang

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor CellsZhe Su, Zhijie Wang, Xiaohui Ni, et al.
Ebiomedicine|July 28, 2022
Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancerYing Zuo, Jia Zhong, Hua Bai, et al.
Cancer Research|September 2, 2018
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint BlockadeZhijie Wang, Jing Zhao, Guoqiang Wang, et al.
Cell|April 13, 2024
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasionShouyan Deng, Yibo Zhang, Huanbin Wang, et al.
BMJ Open|June 4, 2021
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumoursShuhang Wang, Hui-Yao Huang, Dawei Wu, et al.
International Journal of Clinical Oncology|March 30, 2021
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutationsGee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2013
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patientsXiaohui Ni, Minglei Zhuo, Zhe Su, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor CellsZhe Su, Zhijie Wang, Xiaohui Ni, et al.
Ebiomedicine|July 28, 2022
Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancerYing Zuo, Jia Zhong, Hua Bai, et al.
Cancer Research|September 2, 2018
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint BlockadeZhijie Wang, Jing Zhao, Guoqiang Wang, et al.
Cell|April 13, 2024
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasionShouyan Deng, Yibo Zhang, Huanbin Wang, et al.
BMJ Open|June 4, 2021
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumoursShuhang Wang, Hui-Yao Huang, Dawei Wu, et al.
International Journal of Clinical Oncology|March 30, 2021
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutationsGee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2013
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patientsXiaohui Ni, Minglei Zhuo, Zhe Su, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
Pageof 19